Education
About Us
Working with TipRanks
Follow Us
Recce Pharmaceuticals Ltd. (AU:RCE)
:RCE
RESEARCH TOOLSreports
RCE Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.28 - AU$0.56
Previous CloseN/A
Volume21.12K
Average Volume (3M)159.85K
Market Cap
AU$92.28M
Enterprise ValueAU$82.63M
Total Cash (Recent Filing)AU$1.94M
Total Debt (Recent Filing)AU$4.74M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding288,372,340
10 Day Avg. Volume108,737
30 Day Avg. Volume159,851
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)-42.00
Price to Sales (P/S)0.00
P/FCF Ratio-8.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.50Price Target Upside56.25% Upside
Rating ConsensusHold
Number of Analyst Covering0
Recce Pharmaceuticals Ltd. News
PremiumCompany Announcements
Recce Pharmaceuticals Issues New Shares to Support Anti-Infective Development
PremiumCompany Announcements
Recce Pharmaceuticals Announces Quotation of New Shares on ASX
PremiumCompany Announcements
FIL Limited Increases Stake in Recce Pharmaceuticals
PremiumCompany Announcements
Recce Pharmaceuticals Announces Change in Substantial Shareholding
PremiumCompany Announcements
Recce Pharmaceuticals Expands Market Reach with New ASX Securities QuotationOptions Prices
Currently, No data available
---
Ownership Overview
0.12%
Insiders
―
Mutual Funds
― Other Institutional Investors
99.88% Public Companies and
Individual Investors
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.56 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$92.28M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 29, 2025 which is in 45 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Currently, no data Available
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 288,372,340 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
Recce Pharmaceuticals Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.50 (56.25% Upside)
AU$0.50 (56.25% Upside)
Blogger Sentiment
Bullish
AU:RCE Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$14.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.13%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Technical Analysis
Amplia Therapeutics
―
Imugene
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Arovella Therapeutics Limited
―